Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing of the transaction, if completed.

“We thank our stockholders for their strong support for this transaction,” said Michelle Keefe, CEO of Syneos Health. “We look forward to closing the transaction, further executing on our growth priorities, and driving customer success by delivering fit-for-purpose, integrated solutions that help them bring life-saving therapies to patients.”

Completion of the transaction is expected in the second half of 2023, subject to the satisfaction of customary closing conditions, including regulatory approvals.

The final voting results of the Syneos Health special meeting will be reported in a Form 8-K to be filed by Syneos Health with the U.S. Securities and Exchange Commission.

Date of Second Quarter 2023 Results

Syneos Health will file its Quarterly Report on Form 10-Q by Wednesday, August 9, 2023. In light of the pending transaction, Syneos Health will not conduct an earnings conference call.